title: The potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: an update in NHANES 2005-2008.
abstract: This analysis of National Health and Nutrition Examination Survey (NHANES) 2005-2008 data describes the prevalence of risk factors for osteoporosis and the proportions of men and postmenopausal women age 50 years and older who are candidates for treatment to lower fracture risk, according to the new Fracture Risk Assessment Tool (FRAX)-based National Osteoporosis Foundation Clinician's Guide.
  
  
  BACKGROUND
  It is important to update estimates of the proportions of the older US population considered eligible for pharmacologic treatment for osteoporosis for purposes of understanding the health care burden of this disease.
  
  
  METHODS
  This is a cross-sectional study of the NHANES 2005-2008 data in 3,608 men and women aged 50 years and older. Variables in the analysis included race/ethnicity, age, lumbar spine and femoral neck bone mineral density, risk factor profiles, and FRAX 10-year fracture probabilities.
  
  
  RESULTS
  The prevalence of osteoporosis of the femoral neck ranged from 6.0% in non-Hispanic black to 12.6% in Mexican American women. Spinal osteoporosis was more prevalent among Mexican American women (24.4%) than among either non-Hispanic blacks (5.3%) or non-Hispanic whites (10.9%). Treatment eligibility was similar in Mexican American and non-Hispanic white women (32.0% and 32.8%) and higher than it was in non-Hispanic black women (11.0%). Treatment eligibility among men was 21.1% in non-Hispanic whites, 12.6% in Mexican Americans, and 3.0% in non-Hispanic blacks.
  
  
  CONCLUSIONS
  Nineteen percent of older men and 30% of older women in the USA are at sufficient risk for fracture to warrant consideration for pharmacotherapy.
authors: Jean Mayer United States Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA 02111, USA. Bess.Dawson-Hughes@Tufts.edu
authors: B
authors: B
authors: Dawson-Hughes
authors: A C
authors: AC
authors: Looker
authors: A N A
authors: AN
authors: Tosteson
authors: H
authors: H
authors: Johansson
authors: J A
authors: JA
authors: Kanis
authors: L J
authors: LJ
authors: Melton
mesh_terms: D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D044383:Black People / Q000706:statistics & numerical data; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D004363:Drug Utilization / Q000706:statistics & numerical data; D004608:Eligibility Determination; D005260:Female; D005272:Femur Neck / Q000503:physiopathology; D006306:Health Surveys; D006801:Humans; D008159:Lumbar Vertebrae / Q000503:physiopathology; D008297:Male; D017058:Mexican Americans / Q000706:statistics & numerical data; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy* / Q000208:ethnology; D015663:Osteoporosis, Postmenopausal / Q000453:epidemiology; D058866:Osteoporotic Fractures / Q000517:prevention & control; D017410:Practice Guidelines as Topic; D018570:Risk Assessment / Q000379:methods; D017678:Sex Distribution; D014481:United States / Q000453:epidemiology; D044465:White People / Q000706:statistics & numerical data; D001741:Black or African American
chemical_list: D050071:Bone Density Conservation Agents